Ross Stephanie, Anand Sonia S, Joseph Philip, Paré Guillaume
Population Health Research Institute, Hamilton Health Sciences, McMaster University , Hamilton, Ontario L8L 2X2 , Canada.
JRSM Cardiovasc Dis. 2012 Apr 5;1(1):cvd.2012.012001. doi: 10.1258/cvd.2012.012001.
Pharmacogenetics is the study of inherited variation in drug response. The goal of pharmacogenetics is to develop novel ways of maximizing drug efficacy and minimizing toxicity for individual patients. Personalized medicine has the potential to allow for a patient's genetic information to predict optimal dosage for a drug with a narrow therapeutic index, to select the most appropriate pharmacological agent for a given patient and to develop cost-effective treatments. Although there is supporting evidence in favour of pharmacogenetics, its adoption in clinical practice has been slow because of sometimes conflicting findings among studies. This failure to replicate findings may result from a lack of high-quality pharmacogenetic studies, as well as unresolved methodological and statistical issues. The objective of this review is to discuss the benefits of incorporating pharmacogenetics into clinical practice. We will also address outstanding methodological and statistical issues that may lead to heterogeneity among reported pharmacogenetic studies and how they may be addressed.
药物遗传学是对药物反应中遗传变异的研究。药物遗传学的目标是开发新方法,以实现个体患者药物疗效最大化和毒性最小化。个性化医疗有可能利用患者的遗传信息预测治疗指数窄的药物的最佳剂量,为特定患者选择最合适的药物,并开发具有成本效益的治疗方法。尽管有支持药物遗传学的证据,但由于研究结果有时相互矛盾,其在临床实践中的应用进展缓慢。研究结果无法重复可能是由于缺乏高质量的药物遗传学研究,以及尚未解决的方法学和统计学问题。本综述的目的是讨论将药物遗传学纳入临床实践的益处。我们还将探讨可能导致所报道的药物遗传学研究存在异质性的突出方法学和统计学问题,以及如何解决这些问题。